Does pharmacological treatment of ADHD reduce criminality?

A studyopens in new tab/window in the Journal of the American Academy of Child and Adolescent Psychiatry (JAACAP)opens in new tab/window, published by Elsevier, found that pharmacological treatment of attention-deficit/hyperactivity disorder (ADHD) reduced violence- and public-order related crimes. However, it did not reduce other types of crimes, among patients with ADHD in early to late adolescence considered to be in the grey zone (or on the margin) for such treatment.

This study uses variation in healthcare providers treatment preference as the basis for a quasi-experimental design that examines the effect of pharmacological treatment of ADHD on criminality among patients in the grey zone for treatment. Due to their healthcare providers’ treatment preference, some patients may not receive pharmacological treatment.

This study found considerable variation in rates of pharmacological treatment of ADHD between clinics, which impacted patients’ treatment. Pharmacological treatment of ADHD had a protective effect on violence- and public-order related charges, respectively, whereas there was no support for effects on other crimes (e.g., drugs, traffic, and property). Consistent with existing research this study also found that patients with ADHD had a higher risk of all types of crimes compared to the general population.

This is the first study to combine a quasi-experimental design with detailed population-wide registry data on types of crime and multiple years follow-up to assess effects of pharmacological treatment of ADHD on long-term criminal outcomes.Causal knowledge is challenging to establish since large-scale RCTs are ethically and practically unfeasible, while observational studies are limited by many potential confounding variables making treatment and control groups different. To address these issues, this study combines a quasi-experimental design with population-wide registry data on all patients aged 10 to 18 years who were diagnosed with ADHD in 2009-2011 (n=5,624), including their clinics, receipt of ADHD medication, and criminal charges with four years follow-up.

In these “instrumental variable” analyses,provider preference for pharmacological treatment acts as a source of randomization to treatment for patients in the grey zone for treatment where clinicians’ treatment decisions vary most. The logic can be illustrated by two patients with ADHD who are otherwise similar apart from one patient being treated due to seeing a clinician with a high treatment preference, whereas the other is not treated due to seeing a clinician with a low treatment preference. This study is conducted in Norway, importantly characterized by all treatment of ADHD among children and adolescents taking place in the public healthcare system with virtually no private sector, and providers are assigned by patients’ residence.

Pharmacological treatment of ADHD is commonly used in clinical practice, but the impact on crime remains debated. Some clinicians may hold a positive or “liberal” perspective, arguing that pharmacological treatment can reduce criminality by improving core symptoms of ADHD (inattention, hyperactivity, and impulsivity), whereas other clinicians advocate a negative or “restrictive” perspective based on concerns for medicalization, stigma and unecessary side-effects.

While this study finds evidence of causal protective effects of pharmacological treatment on criminality, these effects importantly concern specific types of crime for a particular patient group, and the effect sizes imply that many need to be treated to prevent one additional crime. Nonetheless, this study contributes novel causal knowledge of treatment effects that may be relevant for clinicians and researchers in their overall assessment of the effects of pharmacological treatment of ADHD. This study was first-authored by Dr Tarjei Widding-Havneraas and is a part of the ADHD Controversy Project led by Professor Arnstein Mykletun, which uses this and similar research designs to examine multiple outcomes including crime, education, comorbidities, injuries, and mortality.

Notes for editors

The article is "Effect of Pharmacological Treatment of Attention-Deficit/Hyperactivity Disorder on Criminalityopens in new tab/window," by Tarjei Widding-Havneraas, MPhil, Henrik Daae Zachrisson, PhD, Simen Markussen, PhD, Felix Elwert, PhD, Ingvild Lyhmann, CandPsychol, Ashmita Chaulagain, MPH, Ingvar Bjelland, MD, PhD, Anne Halmøy, MD, PhD, Knut Rypdal, CandJur, Arnstein Mykletun, PhD. It appears in Journal of the American Academy of Child & Adolescent Psychiatry, volume 63 issue 4(April 2024), published by Elsevier.

About JAACAP

Journal of the American Academy of Child and Adolescent Psychiatryopens in new tab/window (JAACAP) is the official publication of the American Academy of Child and Adolescent Psychiatry. JAACAP is the leading journal focusing exclusively on today's psychiatric research and treatment of the child and adolescent. Published twelve times per year, each issue is committed to its mission of advancing the science of pediatric mental health and promoting the care of youth and their families.

The Journal's purpose is to advance research, clinical practice, and theory in child and adolescent psychiatry. It is interested in manuscripts from diverse viewpoints, including genetic, epidemiological, neurobiological, cognitive, behavioral, psychodynamic, social, cultural, and economic. Studies of diagnostic reliability and validity, psychotherapeutic and psychopharmacological treatment efficacy, and mental health services effectiveness are encouraged. The Journal also seeks to promote the well-being of children and families by publishing scholarly papers on such subjects as health policy, legislation, advocacy, culture and society, and service provision as they pertain to the mental health of children and families.

엘스비어 소개

엘스비어는 첨단 정보와 의사결정 지원 분야의 글로벌 선도 기업으로 100년 넘게 과학과 헬스케어의 발전을 지원하며 인류 진보에 기여해 왔습니다. 우리는 170개국 이상에서 학술 및 기업 연구 커뮤니티, 의사, 간호사, 미래의 의료 전문가와 교육자들을 지원합니다. 근거에 기반한 신뢰할 수 있는 과학·의학 콘텐츠와 최첨단 AI 기술을 결합해 중요한 통찰과 혁신적인 솔루션을 제공해, 의미있는 성과를 이루도록 돕고 있습니다. 또한 다양성과 지속 가능성을 제품과 기업 문화 전반에 내재화하며, 우리가 속한 커뮤니티와 협력합니다. 엘스비어 재단opens in new tab/window은 전 세계에서 연구와 보건 파트너십을 지원합니다.

엘스비어는 전문가 및 기업 고객에게 정보 기반의 분석과 의사결정 도구를 제공하는 글로벌 기업 RELXopens in new tab/window의 일원입니다. 자세한 내용은 www.elsevier.com에서 확인할 수 있으며, 소셜미디어 @elsevierconnect를 통해 최신 소식을 받아보실 수 있습니다.